Deutsche Bank AG Buys 55,215 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Deutsche Bank AG boosted its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 8.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 738,745 shares of the company's stock after purchasing an additional 55,215 shares during the quarter. Deutsche Bank AG owned about 0.34% of Hims & Hers Health worth $17,863,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after buying an additional 2,020,722 shares in the last quarter. Renaissance Technologies LLC increased its stake in Hims & Hers Health by 29.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after acquiring an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after purchasing an additional 4,145,305 shares in the last quarter. Geode Capital Management LLC raised its position in Hims & Hers Health by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock valued at $104,724,000 after purchasing an additional 40,447 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in Hims & Hers Health by 17.9% during the fourth quarter. Northern Trust Corp now owns 2,038,202 shares of the company's stock worth $49,284,000 after purchasing an additional 308,886 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HIMS shares. Citigroup reiterated a "sell" rating and issued a $30.00 price target (up previously from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Truist Financial decreased their target price on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Finally, Bank of America upped their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research report on Tuesday, April 29th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $37.67.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $61.82 on Thursday. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The company has a market cap of $13.84 billion, a PE ratio of 140.50 and a beta of 1.84. The firm's 50 day simple moving average is $34.36 and its 200 day simple moving average is $33.16.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company's revenue for the quarter was up 110.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.05 earnings per share. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In other news, insider Michael Chi sold 17,303 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $48.14, for a total value of $832,966.42. Following the transaction, the insider now owns 193,601 shares in the company, valued at approximately $9,319,952.14. The trade was a 8.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the sale, the chief executive officer now owns 97,687 shares of the company's stock, valued at approximately $5,692,221.49. This trade represents a 56.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 563,973 shares of company stock worth $21,951,757 over the last three months. Company insiders own 13.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.